The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

@inproceedings{Kleijn2014TheIV,
  title={The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity},
  author={Anne Kleijn and Jenneke J. Kloezeman and Elike Treffers-Westerlaken and Giulia Fulci and S. Leenstra and Clemens M. F. Dirven and Reno Debets and Martine L. M. Lamfers},
  booktitle={PloS one},
  year={2014}
}
The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising results in various immune-deficient glioma models. However, the role of the immune response in oncolytic adenovirus therapy for glioma has never been explored. To this end, we assessed Delta24-RGD… CONTINUE READING
Highly Cited
This paper has 208 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.
12 Citations
54 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

209 Citations

010020020142015201620172018
Citations per Year
Semantic Scholar estimates that this publication has 209 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Similar Papers

Loading similar papers…